Summary
Metanomics Health GmbH (Metanomics), a subsidiary of BASF SE, is a biotech company that provides metabolic biomarker identification and validation solutions. The company offers analysis of metabolites for various applications in pharma and biotech, biobanking, academia, food and feed industry and diagnostics fields. It develops novel biomarkers for early asymptomatic heart failure and type-2 diabetes. The company’s products include MxP global profiling, MxP targeted profiling, MxP isotope tracer, MxP catecholamines and steroids, MxP biofluids quality control and diagnostic type assays. It conducts biomarker program, which include development of new diagnostic metabolic biomarkers; co-development of companion diagnostic biomarkers; development of metabolic biomarkers; and identification and validation of new drug targets. The company operates in Japan and the US. Metanomics is headquartered in Berlin, Germany.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
Reasons to Buy
Note: Some sections may be missing if data is unavailable for the company
Metanomics Health GmbH (Metanomics), a subsidiary of BASF SE, is a biotech company that provides metabolic biomarker identification and validation solutions. The company offers analysis of metabolites for various applications in pharma and biotech, biobanking, academia, food and feed industry and diagnostics fields. It develops novel biomarkers for early asymptomatic heart failure and type-2 diabetes. The company’s products include MxP global profiling, MxP targeted profiling, MxP isotope tracer, MxP catecholamines and steroids, MxP biofluids quality control and diagnostic type assays. It conducts biomarker program, which include development of new diagnostic metabolic biomarkers; co-development of companion diagnostic biomarkers; development of metabolic biomarkers; and identification and validation of new drug targets. The company operates in Japan and the US. Metanomics is headquartered in Berlin, Germany.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Metanomics Health GmbH
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Metanomics Health GmbH Company OverviewMetanomics Health GmbH Company Snapshot
Metanomics Health GmbH Pipeline Products and Ongoing Clinical Trials Overview
Metanomics Health GmbH – Pipeline Analysis Overview
Metanomics Health GmbH - Key Facts
Metanomics Health GmbH - Major Products and Services
Metanomics Health GmbH Pipeline Products by Development Stage
Metanomics Health GmbH Pipeline Products Overview
Diagnostic Assay - Multiple Sclerosis
Diagnostic Assay - Multiple Sclerosis Product Overview
Diagnostic Assay - Pancreatic Cancer
Diagnostic Assay - Pancreatic Cancer Product Overview
Diagnostic Assay - NSCLC
Diagnostic Assay - NSCLC Product Overview
Diagnostic Assay - Congestive Heart Failure
Diagnostic Assay - Congestive Heart Failure Product Overview
Diagnostic Assay - Non-Alcoholic Steatohepatitis
Diagnostic Assay - Non-Alcoholic Steatohepatitis Product Overview
Diagnostic Assay - Type 2 Diabetes
Diagnostic Assay - Type 2 Diabetes Product Overview
Diagnostic Assay - Type 2 Diabetes Risk
Diagnostic Assay - Type 2 Diabetes Risk Product Overview
Prognostic Assay - Prostate Cancer
Prognostic Assay - Prostate Cancer Product Overview
Prognostic Assay - Congestive Heart Failure
Prognostic Assay - Congestive Heart Failure Product Overview
Metanomics Health GmbH - Key Competitors
Metanomics Health GmbH - Key Employees
Metanomics Health GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Metanomics Health GmbH, Recent Developments
Jun 03, 2016: BASF Hires PwC to Explore Strategic Options For Metanomics Health
Aug 26, 2014: Cenix BioScience and Metanomics Health sign research agreement
Appendix
Methodology
About
Contact
Disclaimer
List of Tables
Metanomics Health GmbH Pipeline Products and Ongoing Clinical Trials Overview
Metanomics Health GmbH Pipeline Products by Equipment Type
Metanomics Health GmbH Pipeline Products by Indication
Metanomics Health GmbH, Key Facts
Metanomics Health GmbH, Major Products and Services
Metanomics Health GmbH Number of Pipeline Products by Development Stage
Metanomics Health GmbH Pipeline Products Summary by Development Stage
Diagnostic Assay - Multiple Sclerosis - Product Status
Diagnostic Assay - Multiple Sclerosis - Product Description
Diagnostic Assay - Pancreatic Cancer - Product Status
Diagnostic Assay - Pancreatic Cancer - Product Description
Diagnostic Assay - NSCLC - Product Status
Diagnostic Assay - NSCLC - Product Description
Diagnostic Assay - Congestive Heart Failure - Product Status
Diagnostic Assay - Congestive Heart Failure - Product Description
Diagnostic Assay - Non-Alcoholic Steatohepatitis - Product Status
Diagnostic Assay - Non-Alcoholic Steatohepatitis - Product Description
Diagnostic Assay - Type 2 Diabetes - Product Status
Diagnostic Assay - Type 2 Diabetes - Product Description
Diagnostic Assay - Type 2 Diabetes Risk - Product Status
Diagnostic Assay - Type 2 Diabetes Risk - Product Description
Prognostic Assay - Prostate Cancer - Product Status
Prognostic Assay - Prostate Cancer - Product Description
Prognostic Assay - Congestive Heart Failure - Product Status
Prognostic Assay - Congestive Heart Failure - Product Description
Metanomics Health GmbH, Key Employees
Metanomics Health GmbH, Other Locations
Glossary
List of Figures
Metanomics Health GmbH Pipeline Products by Equipment Type
Metanomics Health GmbH Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pharmacelsus GmbH
- Pharis Biotec GmbH
- Sphingotec GmbH
